Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) – Pipeline Review, H2 2017’, provides in depth analysis on Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology under development targeting Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1)

The report reviews Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects

The report assesses Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

AstraZeneca Plc

AVEO Pharmaceuticals Inc

Celldex Therapeutics Inc

Daiichi Sankyo Company Ltd

Etubics Corp

F. Hoffmann-La Roche Ltd

GlaxoSmithKline Plc

Hanmi Pharmaceuticals Co Ltd

Hummingbird Bioscience Pte Ltd

ImmunoGen Inc

MediaPharma Srl

Merrimack Pharmaceuticals Inc

Merus NV

Novartis AG

Shanghai Fosun Pharmaceutical (Group) Co Ltd

Sorrento Therapeutics Inc

Symphogen A/S

Takis Srl

XuanZhu Pharma Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC

2.7.10.1) - Overview

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC

2.7.10.1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC

2.7.10.1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC

2.7.10.1) - Companies Involved in Therapeutics Development

AstraZeneca Plc

AVEO Pharmaceuticals Inc

Celldex Therapeutics Inc

Daiichi Sankyo Company Ltd

Etubics Corp

F. Hoffmann-La Roche Ltd

GlaxoSmithKline Plc

Hanmi Pharmaceuticals Co Ltd

Hummingbird Bioscience Pte Ltd

ImmunoGen Inc

MediaPharma Srl

Merrimack Pharmaceuticals Inc

Merus NV

Novartis AG

Shanghai Fosun Pharmaceutical (Group) Co Ltd

Sorrento Therapeutics Inc

Symphogen A/S

Takis Srl

XuanZhu Pharma Co Ltd

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC

2.7.10.1) - Drug Profiles

AV-203 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BA-0702 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CDX-3379 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

elgemtumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ETBX-031 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FCN-411 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-2849330 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HMBD-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

huHER3-8 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

istiratumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lumretuzumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MCLA-125 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Antagonize HER-3 for Breast and Pancrestic Cancers - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MPEV-201959 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

patritumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pirotinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

poziotinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sapitinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

seribantumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sirotinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit EGFR, HER2 and HER3 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Sym-013 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TK-003 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC

2.7.10.1) - Dormant Products

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC

2.7.10.1) - Discontinued Products

Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC

2.7.10.1) - Product Development Milestones

Featured News & Press Releases

Jun 19, 2017: Merrimack Announces Completion of Enrollment in Phase 2 CARRIE Study of MM-141; Data Expected in First Half of 2018

Apr 03, 2017: AVEO Announces Milestone Payment from CANbridge for AV-203

Apr 03, 2017: Hummingbird Bioscience presents update on HMBD-001 at AACR in Washington DC

Mar 30, 2017: Spectrum Pharmaceuticals Announces Initiation of a Phase 2 Trial of Poziotinib in Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations

Mar 27, 2017: Merrimack to Present Data on Istiratumab (MM-141) at the 2017 American Association for Cancer Research Annual Meeting

Dec 08, 2016: Spectrum Pharmaceuticals Highlights Promising Preclinical Data Evaluating Poziotinib in Lung Cancer at the 17th IASLC World Conference on Lung Cancer

Dec 05, 2016: Spectrum Pharmaceuticals Presents Abstract on Poziotinib at the San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas, December 6-10, 2016

Nov 17, 2016: Spectrum Pharmaceuticals Announces Poziotinib Data Presentation at the 17th IASLC World Conference on Lung Cancer in Vienna, Austria, December 4-7, 2016

Oct 25, 2016: Anti-HER3 Monoclonal Antibody Patritumab Selected for I-SPY 2 TRIAL in Breast Cancer

Sep 28, 2016: Merrimack to Present a Poster on Seribantumab (MM-121) at the European Society for Medical Oncology 2016 Congress

Aug 26, 2016: CFDA Granted Approval of Phase I-III Clinical Trials for Sirotinib (XZP - 5491)

Aug 11, 2016: CANbridge Signs Agreement with Boehringer Ingelheim to Manufacture Inhibitory Antibody, CAN-017, for Esophageal Squamous Cell Cancer

Jul 06, 2016: FDA Grants Merrimack Fast Track Designation for Seribantumab (MM-121) in Non-small Cell Lung Cancer

Jun 06, 2016: Kolltan Pharmaceuticals Presents Clinical Data for KTN3379 in an Oral Presentation at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting

May 31, 2016: Daiichi Sankyo Provides Update on HER3-Lung Study of Patritumab in Non-Small Cell Lung Cancer

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Indications, H2 2017

Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Products under Development by Companies, H2 2017 (Contd..4), H2 2017

Number of Products under Investigation by Universities/Institutes, H2 2017

Products under Investigation by Universities/Institutes, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Pipeline by AstraZeneca Plc, H2 2017

Pipeline by AVEO Pharmaceuticals Inc, H2 2017

Pipeline by Celldex Therapeutics Inc, H2 2017

Pipeline by Daiichi Sankyo Company Ltd, H2 2017

Pipeline by Etubics Corp, H2 2017

Pipeline by F. Hoffmann-La Roche Ltd, H2 2017

Pipeline by GlaxoSmithKline Plc, H2 2017

Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2017

Pipeline by Hummingbird Bioscience Pte Ltd, H2 2017

Pipeline by ImmunoGen Inc, H2 2017

Pipeline by MediaPharma Srl, H2 2017

Pipeline by Merrimack Pharmaceuticals Inc, H2 2017

Pipeline by Merus NV, H2 2017

Pipeline by Novartis AG, H2 2017

Pipeline by Shanghai Fosun Pharmaceutical (Group) Co Ltd, H2 2017

Pipeline by Sorrento Therapeutics Inc, H2 2017

Pipeline by Symphogen A/S, H2 2017

Pipeline by Takis Srl, H2 2017

Pipeline by XuanZhu Pharma Co Ltd, H2 2017

Dormant Products, H2 2017

Dormant Products, H2 2017 (Contd..1), H2 2017

Dormant Products, H2 2017 (Contd..2), H2 2017

Discontinued Products, H2 2017

Discontinued Products, H2 2017 (Contd..1), H2 2017

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Top 10 Indications, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports